Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

1.6K
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
1.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mussel Adhesive Protein/Hyaluronic Acid Hydrogels for EGF Delivery and MRSA-Infected Diabetic Wound Repair.

Gels (Basel, Switzerland)·2026
Same author

A Universal Tag To Supercharge Proteins for Cytosolic Delivery.

Molecular pharmaceutics·2026
Same author

Unraveling pH-shifting modulation of gluten-ionic polysaccharide interactions and network structure reconstruction: From physicochemical properties to microstructure.

International journal of biological macromolecules·2026
Same author

The Role of Meditation in Shaping Resilience.

Annals of the New York Academy of Sciences·2026
Same author

A Long-Acting Glucagon-like Peptide 2 Protracted by Coomassie Brilliant Blue to Enhance Intestinal Growth in Mice.

Bioconjugate chemistry·2026
Same author

Radiation-induced MYB reduction unleashes TIM-3 expression in NK cells to attenuate antitumor immunity in colorectal cancer.

Journal of translational medicine·2026
Same journal

Sub1 contributes to heart failure with preserved ejection fraction driven by aging in mice.

Nature communications·2026
Same journal

The BRCA1-A complex restricts replication fork reversal-dependent DNA repair in ATM deficient cells.

Nature communications·2026
Same journal

Signaling downstream of tumor-stroma interaction regulates mucinous colorectal adenocarcinoma apicobasal polarity.

Nature communications·2026
Same journal

Click-polymerized polyenamine membranes for efficient lithium extraction.

Nature communications·2026
Same journal

Joint trajectories of brain atrophy, white matter hyperintensities and cognition quantify brain maintenance.

Nature communications·2026
Same journal

Proton shuttling at electrochemical interfaces under alkaline hydrogen evolution.

Nature communications·2026
See all related articles

Related Experiment Video

Updated: May 2, 2026

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

7.4K

ATP-triggered anticancer drug delivery.

Ran Mo1, Tianyue Jiang1, Rocco DiSanto2

  • 11] Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, North Carolina 27695, USA [2] Molecular Pharmaceutics Division, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA [3] State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.

Nature Communications
|March 13, 2014
PubMed
Summary
This summary is machine-generated.

This study introduces novel nanocarriers that release anticancer drugs in response to adenosine-5'-triphosphate (ATP). This targeted drug delivery enhances cancer treatment efficacy by releasing medication specifically in ATP-rich tumor environments.

More Related Videos

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
08:54

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies

Published on: February 17, 2023

1.7K
Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
09:09

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Published on: June 23, 2020

5.6K

Related Experiment Videos

Last Updated: May 2, 2026

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

7.4K
Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
08:54

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies

Published on: February 17, 2023

1.7K
Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
09:09

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Published on: June 23, 2020

5.6K

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Pharmacology

Background:

  • Stimuli-triggered drug delivery systems enhance therapeutic specificity and efficacy.
  • Adenosine-5'-triphosphate (ATP) is a potential biomarker for targeted drug release.

Purpose of the Study:

  • To develop and evaluate ATP-responsive polymeric nanocarriers for controlled doxorubicin release.
  • To assess the in vitro and in vivo efficacy of these nanocarriers in cancer treatment.

Main Methods:

  • Functionalization of polymeric nanocarriers with an ATP-binding aptamer-DNA motif.
  • Incorporation of doxorubicin as the model anticancer drug.
  • Evaluation of drug release kinetics and cytotoxicity in MDA-MB-231 cancer cells.
  • Assessment of tumor growth inhibition in xenograft mouse models.

Main Results:

  • Nanocarriers demonstrated selective doxorubicin release in ATP-rich environments via a conformational switch.
  • ATP-responsive nanovehicles showed a 3.6-fold increase in cytotoxicity compared to non-responsive ones (IC50 = 0.24 μM).
  • Hyaluronic acid-coated nanocarriers improved chemotherapeutic inhibition of tumor growth in vivo.

Conclusions:

  • ATP-triggered nanocarriers offer a sophisticated approach for targeted anticancer drug delivery.
  • This system effectively differentiates ATP levels for selective drug release, enhancing therapeutic outcomes.
  • The developed nanocarriers show promise for improved cancer chemotherapy with reduced off-target effects.